Manufacturer record
Orison Pharma International Khari: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
8 batches manufactured by Orison Pharma International Khari (Himachal Pradesh) were declared Not of Standard Quality between April 2020 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 25I-T1749, AzithromycinTablets IP (exp Nov 2027). RDTL, Bellary, Karnataka (state lab) found it not of standard quality: Test for Uniformity of Weight of Tablets. Listed in the June 2026 alert.
Records by type
8 records linked to Orison Pharma International Khari in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| AzithromycinTablets IP | Batch 25I-T1749Mfg Dec 2025 · Exp Nov 2027 | Test for Uniformity of Weight of TabletsUniformity of weight/content | RDTL, Bellary, KarnatakaState lab | Jun 2026 |
| Paracetamol Tablets IP 650 mg Arvimol 650 Tablets | Batch 24I-T1956EMfg Dec 2024 · Exp Nov 2026 | The sample is not of standard quality for The reason stated under Description of The tablets.Description | RDTL, GuwahatiCDSCO lab | Dec 2025 |
| Opivas 10 tablets | Batch 23C-T465Mfg Jun 2023 · Exp May 2025 | The sample does not comply with IP requirements for Dissolution test.Dissolution | CDTL MumbaiCDSCO lab | Apr 2025 |
| Opirin-75 Tablets (Aspirin Tablets IP 75mg) | Batch 23G-T1526Mfg Oct 2023 · Exp Sep 2025 | The sample does not comply for description as, almost all the tablets are brittle in nature with rough surface.Description | State Lab MaharashtraState lab | Apr 2025 |
| Opirin-75 Tablets (Aspirin Tablets IP 75mg) | Batch 23K-T2727Mfg Feb 2024 · Exp Jan 2026 | The sample does not comply for description as, the tablets shows uneven light brown coloured spots on the surface of almost all the tablets.Description | State Lab MaharashtraState lab | Apr 2025 |
| FERRIMACK-XT Tablets, Ferrous Ascorbate, Folic Acid & Zinc Tablets | Batch 23C-C081Mfg Jun 2023 · Exp May 2025 | NOT OF STANDARD QUALITY The sample does not meet the criteria for uniformity of weight as per IP. out of 20 capsules weighed, 11 capsules deviates the 10 percent limit as per IP and from that 3 capsules are under double deviation. Hence, Sample does not meet the specifications wrt. Uniformity of Weight of Capsules as per IP.Uniformity of weight/content | State Lab Drugs Control Laboratory, TelanganaState lab | Nov 2024 |
| Sodium Valproate and Valproic Acid Controlled-Release Tablets 200 mg (Opi Soproate - 200) | Batch 23E-T990Mfg Aug 2023 · Exp Jul 2025 | Average weight, Dissolution & DescriptionDissolution | CDTL MumbaiCDSCO lab | Mar 2024 |
| Levocetirizine Hydrochloride Tablets I.P. (ALECET) | Batch 18H-T1108HMfg Nov 2018 · Exp Oct 2020 | AssayAssay | RDTL GuwahatiState lab | Apr 2020 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.